International Track 200

This Nottingham-based company develops, manufactures and tests clinical drugs, saving its pharmaceutical customers time and money. The business, led by chief executive Mark Egerton, 52, was acquired by healthcare investor GHO Capital in December 2015 for an undisclosed sum. Demand for its expertise, especially in the US, pushed international sales to £25.8m last year.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyQuotient Clinical
ActivityPharmaceutical contract researcher
2-yr av intl sales growth pa32.10%
International sales £000s25,828
Total sales £000s31,661

If applicable:

* Supplied by company † Annualised figure